Scilex Holding Company
NASDAQ:SCLXDrug Manufacturers - General
-$0.17 today
- Market cap
- $53.83M
- Beta
- 1.71
- P/E (TTM)
- -0.1
- EPS (TTM)
- -$60.90
Volume 0.00M
Average 0.13M
SCLX Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Scilex Holding CompanyNASDAQ: SCLX
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses turns negative
Q1 FY2026 other income / expenses was -$13.48M, compared with $1.82M a year earlier. Trailing-twelve-month other income / expenses was -$116.93M.
Context
- Other income / expenses amounted to 336.2% of revenue in FY2025, up 317.5 pp from a year earlier.
- Other income / expenses increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other income / expenses holds near -$13.48M or moves back toward the trailing-twelve-month quarterly average of -$29.23M.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- (101.72M) USD
- Year-over-year change
- -1060.7%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (101.72M) | -1060.7% |
| FY2024 | 2024-12-31 | 10.59M | +219.1% |
| FY2023 | 2023-12-31 | (8.89M) | -132.6% |
| FY2022 | 2022-12-31 | 27.27M | +151.9% |
| FY2021 | 2021-12-31 | (52.58M) | — |
Other Income / Expenses vs competitors
How SCLX compares with its peers on the latest reported figures
- SCLX's LTM Mar 2026 other income / expenses of -$116.93M is the lowest of the 9 companies compared; the peer median is $2.92M.
- Its year-over-year change of -775.7% is the 7th highest of 8, against a peer median of -57.4%.
- Other income / expenses amounts to 345.3% of revenue for SCLX, versus a peer median of 52.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $54.3M | +157.6% | — | 43.8% | |
| LTM Mar 2026 | $11.31M | -50.1% | -26.8% | 61.4% | |
| LTM Mar 2026 | $4.27M | -57.4% | -0.2% | 28.4% | |
| LTM Mar 2026 | $4.26M | +130.2% | — | 82.9% | |
CTORCitius Oncology, Inc. | LTM Mar 2026 | $1.57M | — | — | 28.0% |
| LTM Mar 2026 | $1.34M | -87.1% | +1.6% | — | |
| LTM Mar 2026 | -$1.21M | -112.8% | — | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | -$63.9M | -1226.0% | — | 533.2% |
| LTM Mar 2026 | -$116.93M | -775.7% | — | 345.3% | |
| Peer median (excluding SCLX) | $2.92M | -57.4% | -0.2% | 52.6% | |
Competitors are the stored peer set for SCLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 31.32M | 38.03M | 46.74M | 56.59M | 30.25M |
| Cost of Revenue | 3.63M | 10.8M | 15.68M | 16.69M | 15.22M |
| Gross Profit | 27.68M | 27.24M | 31.06M | 39.9M | 15.03M |
| Gross Margin | 88.4% | 71.6% | 66.5% | 70.5% | 49.7% |
| Research & Development | 9.2M | 9.05M | 12.75M | 9.64M | 20.71M |
| Selling, General & Admin | 50.58M | 64.9M | 119.64M | 119.02M | 266.63M |
| Operating Expenses | 63.52M | 77.87M | 136.49M | 123.3M | 287.34M |
| Depreciation & Amortization | 3.78M | 4.45M | 4.15M | 4.05M | 4.62M |
| EBITDA | (72.88M) | (9.3M) | (109.1M) | (66.8M) | (357.95M) |
| EBITDA Margin | -232.7% | -24.5% | -233.4% | -118.0% | -1183.2% |
| Operating Income | (35.84M) | (50.63M) | (105.43M) | (83.4M) | (272.3M) |
| Operating Margin | -114.4% | -133.1% | -225.6% | -147.4% | -900.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 11.76M | 9.6M | 1.07M | 1.96M | 11.46M |
| Other Income / Expenses | (52.58M) | 27.27M | (8.89M) | 10.59M | (101.72M) |
| Income Before Tax | (88.42M) | (23.36M) | (114.32M) | (72.81M) | (374.03M) |
| Pre-Tax Margin | -282.3% | -61.4% | -244.6% | -128.7% | -1236.3% |
| Income Tax Expense | 5K | 4K | 13K | (1K) | 26K |
| Net Income | (88.42M) | (23.36M) | (114.33M) | (72.81M) | (358.73M) |
| Net Margin | -282.4% | -61.4% | -244.6% | -128.7% | -1185.8% |
| EPS (Basic) | (23.29) | (6.09) | (44.85) | (19.43) | (36.48) |
| EPS (Diluted) | (23.29) | (6.09) | (44.85) | (19.43) | (36.48) |
| Weighted Avg Shares | 3.8M | 3.83M | 3.72M | 6.95M | 11.03M |
| Weighted Avg Shares (Diluted) | 3.8M | 3.83M | 3.72M | 6.95M | 11.03M |
Scilex Holding Company
NASDAQ:SCLX
Intrinsic Alpha fair value
Locked
Current Price
$6.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.